DOCSLIB.ORG

Cellular Responses to 2009 Pandemic H1n1 Influenza in A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cellular Responses to 2009 Pandemic H1n1 Influenza in A Characterisation of Cellular Responses to Pandemic Influenza in Naturally Infected Individuals Shaima Begom Imperial College London National Heart and Lung Institute Submitted for the degree of PhD February 2015 I DECLARATION OF ORIGINALITY I certify that this thesis, and the research to which it refers, are the product of my own work, conducted during the years 2010 and 2014 of the PhD in the Section of Respiratory Medicine at Imperial College London. Any ideas or quotations from the work of other people published or otherwise, or from my own previous work are fully acknowledged in accordance with the standard referencing practices of the discipline. Furthermore, I would like to acknowledge Professor Ajit Lalvani and Dr Saranya Sridhar who designed the ImmunoFlu study cohort. Dr Sridhar recruited subjects for the ImmunoFlu study, and I participated in collection and bio-banking of biological samples during the PhD period. Dr Sridhar and I equally contributed to the laboratory work presented in Results sections 3.2 and 3.3 of this thesis. II COPYRIGHT DECLARATION “The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the licence terms of this work.” Registry, Imperial College London. “Since 2003, ownership of copyright in original research articles remains with the Authors*, and provided that, when reproducing the Contribution or extracts from it, the Authors acknowledge first and reference publication in the Journal, the Authors retain the following non-exclusive rights: a. To reproduce the Contribution in whole or in part in any printed volume (book or thesis) of which they are the author(s). b. They and any academic institution where they work at the time may reproduce the Contribution for the purpose of course teaching. c. To reuse figures or tables created by them and contained in the Contribution in other works created by them. d. To post a copy of the Contribution as accepted for publication after peer review (in Word or Tex format) on the Author's own web site, or the Author's institutional repository, or the Author's funding body's archive, six months after publication of the printed or online edition of the Journal, provided that they also link to the Journal article on NPG's web site (eg through the DOI). NPG encourages the self-archiving of the accepted version of your manuscript in your funding agency's or institution's repository, six months after publication. This policy complements the recently announced policies of the US National Institutes of Health, Wellcome Trust and other research funding bodies around the world. NPG recognizes the efforts of funding bodies to increase access to the research they fund, and we strongly encourage authors to participate in such efforts. Authors wishing to use the published version of their article for promotional use or on a web site must request in the normal way.* Commissioned material is still subject to copyright transfer conditions.” Nature Publishing Group, Terms of re-use by Authors. III ACKNOWLEDGEMENTS Firstly, all praise is to Allah. A special thank you to my supervisors Prof Ajit Lalvani and Dr Saranya Sridhar, for giving me the opportunity and inspiration to undertake this project, for training me in various techniques and for support, advice and insightful discussions throughout. Thank you to all the volunteers who donated samples used in this study. Thanks to everyone in the department of Respiratory Medicine at St Mary’s hospital for making the last 4 years an enjoyable experience. The ‘Flubercoidosis Protocols’ will serve as a constant reminder to me of the wonderful friends and colleagues I have worked with. Thank you to Robert Sampson for help and advice on the flow cytometry staining panel. Thank you to Dr Nazneen Siddiqui for your encouragement during the final phase of writing this thesis. This thesis is dedicated to my family; my parents, husband and siblings, your constant support and patience made this dream a reality. IV AUTHORED PUBLICATIONS AND PRESENTATIONS Published papers Sridhar S, Begom S, Bermingham A, Ziegler T, Roberts KL, Barclay WS, Openshaw, P, Lalvani A. Predominance of heterosubtypic IFN-gamma-only-secreting effector memory T cells in pandemic H1N1 naive adults. European Journal of Immunology. 2012 Nov; 42(11):2913-24. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W., Carman W., Lalvani A. Higher incidence of natural infection during the third pandemic wave compared to the second pandemic wave. Emerging Infectious Diseases, 2013. 19: 1866-1869. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W., Carman W., Barclay WS, Lalvani A. Cellular Immune Correlates for protection against pandemic influenza. Nature Medicine, 2013 Oct, 19(10):1305-12. Sridhar S, Begom S, Hoschler K, Bermingham A, Adamson W, Carman W, Riley S, Lalvani A. Longevity and Determinants of Protective Humoral Immunity Following Pandemic Influenza Infection. AJRCCM, 2014 Dec. [Epub ahead of print]. Manuscripts in preparation Begom S, Sridhar S, et al., Evolution, longevity and immune determinants of protection-associated CD8+ effector T cells following natural pandemic influenza infection. Begom S, Sridhar S, Siddiqui N, Kwok J and Lalvani A. IFN-γ/IL-2 fluorescence- immunospot: a reproducible assay for quantifying clinically relevant functional T cell subsets in human studies. Conference presentations V 6th - 10th Dec 2010. British Society for Immunology Congress, Liverpool, UK. Poster presentation: Shaima Begom, Saranya Sridhar, Alison Bermingham, Samuel Bremang, Lisa Grass, Murphy Magtoto, Lee Potiphar, Peter Openshaw, Ajit Lalvani. ‘Cross-reactive T cells to pandemic influenza H1N1 are predominantly of an effector phenotype’. 29th May – 1st June, 2013. Mechanisms of Antigen Specific Immune Responses (MASIR), Dubrovnik, Croatia. Poster presentation: Shaima Begom, Saranya Sridhar, Chi Kwok, Nazneen Siddiqui, Prof Ajit Lalvani. ‘Assessing clinical performance parameters of a fluorescence-immunospot assay to quantify dual cytokine-secreting cells’. 5th -10th September 2013. Options for the Control of Influenza VIII. Cape Town, South Africa. Poster presentation: Saranya Sridhar, Shaima Begom, Alison Bermingham, Katja Hoschler, Walt Adamson, William Carman, Thomas Bean, Wendy Barclay, Jonathan Deeks, Ajit Lalvani. ‘CD8+ T cells correlate with protection against symptomatic illness following natural pandemic influenza infection in humans’. VI ABBREVIATIONS AF700 Alexa Fluor 700 APC Antigen presenting cell (or allophycocyanin antibody congugate) APC-Cy7 Allophycocyanin conjugated to a Cyanine-7 ASC Antibody secreting cell BSA Bovine serum albumin BV570 Brilliant Violet 570 CD Cluster of differentiation CI Confidence interval CMV Cytomegalovirus CTL Cytotoxic T lymphocyte CV Coefficient of variation DC Dendritic cell DMSO Dimethyl sulphoxide EBV Epstein bar virus EDTA Ethylenediaminetetraacetic acid ELISpot Enzyme-linked immunosorbent spot ESAT-6 6kDa early secreted antigenic target from Mycobacterium tuberculosis FACS Fluorescence activated cell sorting FBS Fetal bovine serum Fig. Figure FITC Fluorescin Isothiocyanate FMO Fluorescence minus one GALT Gut-associated lymphoid tissue Gamma-delta HA Haemagglutinin HAI Haemagglutination inhibition HIV-1 Human immunodeficiency virus-1 HLA Human leukocyte antigen HSI Heterosubtypic immunity IAV Influenza A virus ICS Intracellular cytokine staining IFN Interferon IFN- Interferon-gamma IgG Immunoglobulin G IgA Immunoglobulin A IgM Immunoglobulin M IL-1 Interleukin-1 IL-2 Interleukin-2 IL-4 Interleukin-4 IL-5 Interleukin-5 IL-6 Interleukin-6 IL-10 Interleukin-10 IL-12 Interleukin-12 IL-13 Interleukin-13 IL-17 Interleukin-17 ILI Influenza-like illness ILC Innate lymphoid cell iNKT Invariant Natural Killer T cell VII IQR Interquartile range L/D Live/Dead LAIV Live attenuated influenza vaccine LCMV Lymphocytic choriomeningitis virus LM Listeria monocytogenes LRT Lower respiratory tract M1 Matrix protein 1 mAb Monoclonal antibody MACS Magnetic activated cell sorting MAIT Mucosa-associated invariant T cell MALT Mucosa-associated lymphoid tissue MHC Major Histocompatibility Complex MOI Multiplicity of infection NA Neuraminidase NALT Nasopharynx-associated lymphoid tissue NK Natural Killer NLR Nod-like receptor NP Nucleoprotein OR Odds ratio PB1 Polymerase basic protein 1 PBMC Peripheral blood mononuclear cell PBS Phosphate buffered saline PE Phycoerythrin PE-CF594 Phycoerithrin conjugated to Carmen Fluorochrome 594 PE-Cy5 Phycoerythrin conjugated to Cyanine-5 PE-Cy7 Phycoerythrin conjugated to Cyanine-7 PerCP-Cy5.5 Peridinin Chlorophyll Protein conjugated to Cyanine-5.5 pH1N1 2009 pandemic H1N1 PHE Public Health England PMA/I Phorbol myristate acetate/Ionomycin PPD Purified protein derivative QDot605 Quantum Dot 605 Qdot655 Quantum Dot 655 RT-PCR Reverse transcriptase polymerase chain reaction SA Strepavidin SD Standard deviation SEM Standard error of mean SFC Spot-forming cell Tcm Central memory T cell TCR T cell receptor Tem Effector memory T cell Temra Late effector memory T cell Th1 T helper 1 Th2 T helper 2 Th17 T helper 17 TIV Trivalent inactivated vaccine TLR Toll-like receptor TNF- Tumour necrosis factor alpha Trm Resident memory T cell URT Upper
Load more

Recommended publications
  • Characterizing Immunogenetic Factors Associated with Influenza Cross- Reactive Responses and Disease Severity
    Characterizing immunogenetic factors associated with Influenza cross- reactive responses and disease severity By Dr. Yoav Keynan M.D A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of DOCTOR OF PHILOSOPHY Department of Medical Microbiology University of Manitoba Winnipeg Copyright © 2013 by Yoav Keynan Acknowledgements: To my committee members: Dr. Coombs, Dr. Aoki, Dr. Soussi-gounni for your patience and invaluable advice, with diverse backgrounds, your input has been instrumental to the completion of this project. To my mentor, Dr. Fowke- for making my decision to migrate to your lab the best career decision I have made; for guiding me in this research project and for being an advocate and supporter along the course of the years. The most important lessons I have learned from you are not limited to science or grant writing, but more importantly, the optimism and positive attitude (sometimes bordering with delusion) that instills belief and motivation. To Dr. Rubinstein- for your advice and mentoring during the combined infectious diseases and PhD training. For the open doors, listening and support along the frequently bifurcating paths. To the Fowke lab team past and present- that make this lab a second home. Special thanks to Steve for your assistance over the past 8 years. To Dr. Plummer, for giving me the initial opportunity to embark on a research career in Winnipeg. To Dr. Ball for your support and collaboration. To the Ball Lab members, for the numerous fruitful discussions. To Dr. Meyers for the numerous projects and continued collaboration.
    [Show full text]
  • ESCMID Online Lecture Library © by Author
    Albert Osterhaus Head Dept Virology Chairman ESWI CSO Viroclinics-Biosciences BV Library Pandemic flu and the anti-H1N1 vaccine: Lecture a retrospective view. author Onlineby © ESCMID ESCMID conference on the impact of vaccines on Public Health Prague, 2nd April 2011 Human influenza: three appearances Library Seasonal influenza (A: H3N2, H1N1; B) Lecture Avian influenza author (A: H7N7, H5N1…)Online by © PandemicESCMID influenza (A: H1N1, H2N2, H3N2, H1N1…?) INFLUENZA A VIRUS Recent zoonotic transmissions Library Subtype Country Year # Cases # Deaths H7N7 UK Lecture1996 1 0 H5N1 Hongkong 1997 18 6 H9N2 SE-Asia 1999author >2 0 H5N1 HongkongOnlineby 2003 2? 1 H7N7 Netherlands© 2003 89 1 H7N2 USA 2003 1 0 H7N3 Canada 2004 2 0 H5N1ESCMIDSE-Asia/M-East/ 2003-11 .>500 >300* Europe/W-Africa *CFR ~ 60% Library Lecture author Onlineby © ESCMID Confirmed H5N1 avian influenza virus endemic areas (poultry and wild birds) since 2003 Avian influenza A H5N1 virus - HA: Receptor specificity - Library Shinya et al., Nature 440, 2006 Lecture Van Riel et al., Science 2006 author Van Riel et al., Online Am J Pathol 2007 by Van Riel et al., © Am J Pathol 2009 Van Riel et al., ESCMID Am J Pathol 2010 Library Lecture author Onlineby © ESCMID Introduction - Attachment to the upper respiratory tract - Seasonal H3N2 Pandemic H1N1 HPAIV H5N1 Last four pandemics Library Lecture Credit: US National Museum of Health and Medicine author 1918 1957Online 1968 2009 “Spanish Flu” “Asian Flu” by “Hong Kong Flu” © ”Swine Flu” >40 million deaths 1-4 million deaths 1-4million deaths ??? A(H1N1)ESCMIDA(H2N2) A(H3N2) A(H1N1) Library Lecture author Onlineby © ESCMID Air traffic from Mexico ~ 1998 PB2,PA: Triple reassortant ~ 1968 ~ 1998 PB1: LibraryN-America ~ 1918 Classical swine HA, NP, NS: Lecture ~ 1979 NA, MA: authorEurasian swine Eurasia Onlineby A/California/4/2009 © PB2 PB1 The H1N1v flu virus PA Courtesy: Ron Fouchier HA NP ESCMID NA MA NS Library Lecture author Onlineby © ESCMID The Mexican flu virus..
    [Show full text]
  • Pre-Existing Immunity Provides a Barrier to Airborne Transmission of Influenza Viruses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.15.103747; this version posted June 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Pre-existing immunity provides a barrier to airborne transmission of influenza viruses Valerie Le Sage1, Jennifer E. Jones1, Karen A. Kormuth1^, William J. Fitzsimmons2, Eric Nturibi1, Gabriella H. Padovani1, Claudia P. Arevalo4, Andrea J. French1, Annika J. Avery1, Richard Manivanh1, Elizabeth E. McGrady1, Amar R. Bhagwat1^, Adam S. Lauring2,3, Scott E. Hensley4, Seema S. Lakdawala1,5* 1 - Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 2 – Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 3 – Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 4 – Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 5 - Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219 * Send all correspondence to [email protected] ^ Current position - KAK is an Assistant Professor at Bethany College, Bethany, WV and ARB is a Senior Project Engineer at II-VI Aerospace & Defense in Dayton, OH. Abstract Human-to-human transmission of influenza viruses is a serious public health threat, yet the precise role of immunity from previous infections on the susceptibility to airborne viruses is still unknown. Using human seasonal influenza viruses in a ferret model, we examined the roles of exposure duration and heterosubtypic immunity on influenza transmission. We found that airborne transmission of seasonal influenza strains is abrogated in recipient animals with pre-existing non- neutralizing immunity, indicating that transmissibility of a given influenza virus strain should be examined in the context of ferrets that are not immunologically naïve.
    [Show full text]
  • B Cell Responses Against Influenza Viruses
    viruses Review B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat Jenna J. Guthmiller 1,* , Henry A. Utset 1 and Patrick C. Wilson 1,2 1 Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA; [email protected] (H.A.U.); [email protected] (P.C.W.) 2 Committee on Immunology, University of Chicago, Chicago, IL 60637, USA * Correspondence: [email protected] Abstract: Antibodies are critical for providing protection against influenza virus infections. However, protective humoral immunity against influenza viruses is limited by the antigenic drift and shift of the major surface glycoproteins, hemagglutinin and neuraminidase. Importantly, people are exposed to influenza viruses throughout their life and tend to reuse memory B cells from prior exposure to generate antibodies against new variants. Despite this, people tend to recall memory B cells against constantly evolving variable epitopes or non-protective antigens, as opposed to recalling them against broadly neutralizing epitopes of hemagglutinin. In this review, we discuss the factors that impact the generation and recall of memory B cells against distinct viral antigens, as well as the immunological limitations preventing broadly neutralizing antibody responses. Lastly, we discuss how next-generation vaccine platforms can potentially overcome these obstacles to generate robust and long-lived protection against influenza A viruses. Keywords: influenza viruses; humoral immunity; broadly neutralizing antibodies; imprinting; Citation: Guthmiller, J.J.; Utset, H.A.; hemagglutinin; germinal center; plasma cells Wilson, P.C. B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat. Viruses 2021, 13, 1.
    [Show full text]
  • The Compelling Need for Game-Changing Influenza Vaccines
    THE COMPELLING NEED FOR GAME-CHANGING INFLUENZA VACCINES AN ANALYSIS OF THE INFLUENZA VACCINE ENTERPRISE AND RECOMMENDATIONS FOR THE FUTURE OCTOBER 2012 The Compelling Need for Game-Changing Influenza Vaccines An Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future Michael T. Osterholm, PhD, MPH Nicholas S. Kelley, PhD Jill M. Manske, PhD, MPH Katie S. Ballering, PhD Tabitha R. Leighton, MPH Kristine A. Moore, MD, MPH The Center for Infectious Disease Research and Policy (CIDRAP), founded in 2001, is a global leader in addressing public health preparedness and emerging infectious disease response. Part of the Academic Health Center at the University of Minnesota, CIDRAP works to prevent illness and death from targeted infectious disease threats through research and the translation of scientific information into real-world, practical applications, policies, and solutions. For more information, visit: www.cidrap.umn.edu. This report was made possible in part by a grant from the Alfred P. Sloan Foundation. This report is available at: www.cidrap.umn.edu This report was produced and designed by Betsy Seeler Design. © 2012 Regents of the University of Minnesota. All rights reserved. Contents Preface...............................................................................................................................................................2 Executive Summary..........................................................................................................................................5 Chapter.1.
    [Show full text]
  • Development of Universal Influenza Vaccine in Chicken with Insights On
    Development of universal Influenza vaccine in chicken with insights on the extracellular domain of Matrix protein 2 DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Mohamed Elaish, B.V.Sc, M.V.Sc Graduate Program in Comparative and Veterinary Medicine The Ohio State University 2016 Dissertation Committee: Dr. Chang Won Lee (Advisor) Dr. Yehia M. Saif Dr. Daral Jackwood Dr. Renukaradhya Gourapura Dr. Quihong Wang Copyrighted by Mohamed Elaish 2016 Abstract Avian influenza (AI) is an infectious disease of avian species caused by type A influenza viruses with a significant economic impact on the poultry industry. In addition to affecting poultry, different subtypes of AI viruses can infect other species, thus complicating prevention and control. Vaccination is one of the main disease prevention strategies in many countries worldwide. Current influenza vaccines based on the highly variable hemagglutinin (HA) protein can provide effective protection against specific, antigenically matching virus, but little protection against more distant strains, even those belonging to the same subtype, and they do not provide heterosubtypic immunity. Therefore, to protect chickens against new strain of AI virus, as well as control and prevent virus spread among farms, new vaccines needed to be designed to overcome the limitations of conventional vaccines. One of the approaches for new vaccine design is targeting conserved regions of the influenza genome as possible universal vaccines to induce cross protective immunity against different strains and to eliminate constant vaccine updates based on circulating virus. The extracellular domain of ion channel M2 protein (M2e) is highly conserved among different AI strains suggesting that it would be a promising candidate for developing a universal influenza vaccine.
    [Show full text]
  • Antivirals Publications, 2010–2011
    APPENDIX 12 Antivirals publications, 2010–2011 1. 2009. [Black triangle down] Tamiflu – the wrong message? Drug Ther.Bull. 47:97. doi:47/9/97 [pii];10.1136/dtb.2009.08.0034 [doi]. 2. 2009. A caution about giving Tamiflu to children. Child Health Alert. 27:4–5. 3. 2009. Antiviral drugs for influenza. Med.Lett.Drugs Ther. 51:89–92. 4. 2009. Campus response to novel influenza H1N1. J.Am.Coll.Health 58:281–289. doi:U6265414166J437M [pii];10.1080/07448480903482510 [doi]. 5. 2009. Case management for influenza. J.Indian Med.Assoc. 107:528–530. 6. 2009. Epidemiology of seasonal, avian and pandemic influenza. J.Indian Med.Assoc. 107:506–507. 7. 2009. Foreword: this issue of the Seton Hall Law Review presents contributions to Preparing for Pharmaceutical Response to Pandemic Influenza, a two-day Symposium held at Seton hall University School of Law in the fall of 2008. Seton.Hall.Law Rev. 39:1103–1109. 8. 2009. Pandemic preparedness. Alta.RN. 65:20–27. 9. 2009. Update on oseltamivir-resistant pandemic A (H1N1) 10. 2009 influenza virus: January 2010. Wkly.Epidemiol.Rec. 85:37–40. 11. 2010. [Technical report on the 2009 influenza A (H1N1) pandemic]. An.Pediatr.(Barc.) 72:81–35. doi:S1695-4033(09)00614-6 [pii];10.1016/j.anpedi.2009.11.002 [doi]. 12. 2010. [Treatment with antiviral agents]. An.Pediatr.(Barc.) 72:81–85. doi:S1695-4033(09)00621-3 [pii];10.1016/j.anpedi.2009.11.009 [doi]. 13. 2010. 2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care – New York City, 2009.
    [Show full text]
  • Protection Against Influenza A(H5N1) by Primary Infection with Influenza A(H3N2) and MVA-Based Vaccination
    Protection Against Influenza A(H5N1) by Primary Infection with Influenza A(H3N2) and MVA-based Vaccination Bescherming Tegen Influenza A(H5N1) door Primaire Infectie met Influenza A(H3N2) en op MVA gebaseerde Vaccinatie Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. H.G. Schmidt en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op donderdag 3 september 2009 om 13:30 uur door Johannes Henricus Cornelus Maria Kreijtz geboren te Vorstenbosch Protection Against Influenza A(H5N1) by Primary Infection with Influenza A(H3N2) and MVA-based Vaccination Thesis, Erasmus University, Rotterdam, the Netherlands. With summary in Dutch ISBN: 978-94-9032-001-0 ©J.H.C.M. Kreijtz, 2009 All rights reserved. Save exceptions stated by law, no part of this publication may be produced or transmitted in any form or by any means, electronic or mechanical, without prior written permission of the author, or where appropriate, of the publisher of the articles Voor ons pap en mam Promotie commissie Promotor: Prof.dr. A.D.M.E. Osterhaus Co-promotor: Dr. G.F. Rimmelzwaan Overige leden: Prof.dr. T. Kuiken Prof.dr. G. Sutter Prof.dr. B.N. Lambrecht The research described in this thesis was financially supported byZonMW Grant 91402008 (Netherlands Influenza Vaccine Research Consortium (NIVAREC)) Financial support by the following companies and foundations is gratefully acknowledged: Viroclinics Solvay Biologicals Nobilon International BV Roche
    [Show full text]
  • Narcolepsy and Influenza Vaccination—The Inappropriate Awakening of Immunity
    Editorial Page 1 of 6 Narcolepsy and influenza vaccination—the inappropriate awakening of immunity Anoma Nellore1, Troy D. Randall2,3 1Department of Medicine, Division of Infectious Diseases; 2Division of Clinical Immunology, 3Division of Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA Correspondence to: Troy D. Randall. Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Birmingham, 1720 2nd AVE S. SHEL 507, Birmingham, AL 35294, USA. Email: [email protected]. Submitted Sep 24, 2016. Accepted for publication Sep 27, 2016. doi: 10.21037/atm.2016.10.60 View this article at: http://dx.doi.org/10.21037/atm.2016.10.60 Introduction are associated with the onset of narcolepsy symptoms. However, the way these infections promote the onset of Narcolepsy is a chronic neurological disorder characterized narcolepsy is not entirely clear. by an inability to regulate sleep/wake cycles leading to abruptly occurring periods of daytime sleepiness, cataplexy, hypnogogic hallucinations and disrupted nocturnal sleep (1). Link with influenza vaccination The symptoms of narcolepsy often emerge over time and The appearance of the H1N1 pandemic strain of influenza a definitive diagnosis requires a combination of behavioral in 2009 prompted the rapid development and distribution and biochemical tests. As a result, the identification of of vaccines containing antigens from the new virus. These narcolepsy in any particular patient is difficult and is often delayed by up to a decade following the initial onset of vaccines included (among others), Pandemrix, which was symptoms. administered to approximately 30M patients in Europe, The symptoms of narcolepsy are due to impaired Focetria, which was administered to approximately 25M signaling by the neuropeptide, hypocretin (HCRT— patients globally, including Europe, and Arepanrix, which also known as orexin) (2-4).
    [Show full text]
  • T Cell Immunity Against Influenza
    viruses Review T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine Anna Schmidt and Dennis Lapuente * Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany; [email protected] * Correspondence: [email protected] Abstract: Current flu vaccines rely on the induction of strain-specific neutralizing antibodies, which leaves the population vulnerable to drifted seasonal or newly emerged pandemic strains. Therefore, universal flu vaccine approaches that induce broad immunity against conserved parts of influenza have top priority in research. Cross-reactive T cell responses, especially tissue-resident memory T cells in the respiratory tract, provide efficient heterologous immunity, and must therefore be a key component of universal flu vaccines. Here, we review recent findings about T cell-based flu immunity, with an emphasis on tissue-resident memory T cells in the respiratory tract of humans and different animal models. Furthermore, we provide an update on preclinical and clinical studies evaluating T cell-evoking flu vaccines, and discuss the implementation of T cell immunity in real-life vaccine policies. Keywords: influenza; vaccine; influenza vaccine; T cells; tissue-resident memory T cells; TRM; universal flu vaccine Citation: Schmidt, A.; Lapuente, D. T Cell Immunity against Influenza: The 1. Introduction Long Way from Animal Models Influenza viruses are a constant threat to the world community. Globally, 290,000– Towards a Real-Life Universal Flu 650,000 seasonal influenza-associated deaths are estimated with the highest mortality rate Vaccine. Viruses 2021, 13, 199. in sub-Saharan Africa and southeast Asia [1].
    [Show full text]
  • Towards a Universal Influenza Vaccine: Different Approaches for One Goal Giuseppe A
    Sautto et al. Virology Journal (2018) 15:17 DOI 10.1186/s12985-017-0918-y REVIEW Open Access Towards a universal influenza vaccine: different approaches for one goal Giuseppe A. Sautto1, Greg A. Kirchenbaum1 and Ted M. Ross1,2* Abstract Influenza virus infection is an ongoing health and economic burden causing epidemics with pandemic potential, affecting 5–30% of the global population annually, and is responsible for millions of hospitalizations and thousands of deaths each year. Annual influenza vaccination is the primary prophylactic countermeasure aimed at limiting influenza burden. However, the effectiveness of current influenza vaccines are limited because they only confer protective immunity when there is antigenic similarity between the selected vaccine strains and circulating influenza isolates. The major targets of the antibody response against influenza virus are the surface glycoprotein antigens hemagglutinin (HA) and neuraminidase (NA). Hypervariability of the amino acid sequences encoding HA and NA is largely responsible for epidemic and pandemic influenza outbreaks, and are the consequence of antigenic drift or shift, respectively. For this reason, if an antigenic mismatch exists between the current vaccine and circulating influenza isolates, vaccinated people may not be afforded complete protection. There is currently an unmet need to develop an effective “broadly-reactive” or “universal” influenza vaccine capable of conferring protection against both seasonal and newly emerging pre-pandemic strains. A number of novel influenza vaccine approaches are currently under evaluation. One approach is the elicitation of an immune response against the “Achille’s heel” of the virus, i.e. conserved viral proteins or protein regions shared amongst seasonal and pre- pandemic strains.
    [Show full text]
  • Establishment of Memory CD8+ T Cells with Live Attenuated Influenza Virus
    1 2 Establishment of memory CD8+ T cells with live attenuated influenza 3 virus (LAIV) across different vaccination doses 4 5 6 7 Zhongfang Wang1*, Lukasz Kedzierski1*, Simone Nuessing1, Brendon Yew Loong Chua1, 8 Sergio M Quiñones-Parra1, Victor C. Huber3, David C Jackson1, Paul G Thomas4 and 9 Katherine Kedzierska1# 10 11 12 1Department of Microbiology and Immunology, University of Melbourne, at the Peter 13 Doherty Institute for Infection and Immunity, Parkville VIC 3010, Australia; 3Division of 14 Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota, 15 Vermillion, SD, USA, 4Department of Immunology, St Jude Children’s Research Hospital, 16 Memphis, TN, USA. 17 18 19 20 *These authors contributed equally to this work 21 22 Running title: CD8+ T cells and LAIV vaccination 23 24 25 Correspondence: A/Prof Katherine Kedzierska, Department of Microbiology and 26 Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and 27 Immunity, VIC 3010, Australia. 28 Email: [email protected] 29 30 31 Keywords CD8+ T cells, influenza infection, live attenutated, Vaccine 32 Abbreviations LAIV: live attenuated influenza virus; BAL: bronchoalveolar lavage; 33 hemagglutinin (HA) and the neuraminidase (NA); cold-adapted (ca); attenuated (att); 34 temperature sensitive (ts); neutralizing (NT); hemagglutinin inhibition (HI). 35 Word counts: 3679 36 37 38 1 39 ABSTRACT 40 FluMist has been used in children and adults for more than ten years. As pre-existing 41 CD8+ T-cell memory pools can provide heterologous immunity against distinct influenza 42 viruses, it is important to understand influenza-specific CD8+ T-cell responses elicited by 43 different LAIV regimens.
    [Show full text]